OWKIN

✨ K Navigator is here! At Owkin, we believe the complexity of biology goes beyond what human intelligence can tackle alone. That’s why today we are launching K Navigator, a ground-breaking agentic co-pilot to speed up breakthroughs in biomedical research by 20x. Today, we’re excited to introduce K Navigator with a special keynote featuring our Co-founder & CEO, Thomas Clozel, along with the team behind its creation. Join us as we unveil this cutting-edge co-pilot, now available for free to academic researchers. This is a big step forward in our journey towards achieving Biological Artificial Super Intelligence and we’re so proud to share it with you! 📽️ Watch the keynote Get started with K Navigator: https://lnkd.in/d3JATe8t And this is just the beginning! Later this year we’ll be introducing K Pro for pharma and industry.

Owkin Discovery AI: strong early results Last week, we published a blog about our Discovery AI, our multimodal model for ranking novel, clinically relevant drug targets. This week, we’re sharing new model performance study results: ✅ 16.8× better than DepMap ✅ 2.8× better than Open Targets ✅ 19.6× better than random Trained across 30+ cancer types, Discovery AI learns from spatial omics, transcriptomics, histology & genomics, and outperforms leading public tools in ranking Phase 2 drug targets. 👉 See the results: https://lnkd.in/eCm3pNye

MOSAIC just hit 2,500 samples! Thanks to our partner research hospitals across Europe and the US, MOSAIC has grown into one of the most extensive and comprehensive spatial omics datasets in cancer research. It spans 10 cancer types and 6 data modalities, including whole-tissue spatial and single-cell omics to capture the complexity of the tumor microenvironment. Earlier this year, we launched MOSAIC Window, a subset of the dataset available via the EGA where researchers can apply for access, starting with glioblastoma and muscle-invasive bladder cancer. More indications will follow soon. The MOSAIC Window data can also be explored interactively through K-Navigator, our agentic AI co-pilot for researchers. https://lnkd.in/dKipUNkV Apply to explore MOSAIC-Window here: https://lnkd.in/e_awrTTK Follow the MOSAIC journey here: https://lnkd.in/eVyBR4r3 Gustave Roussy, CHUV | Lausanne university hospital, Universitätsklinikum Erlangen, Charité - Universitätsmedizin Berlin, University of Pittsburgh

“We’re at the precipice of doing something that nobody has done before” For our new Partners in Science film, Devin Dressman, Adrian Lee, Arjun Pennathur, MD, Maureen Lyons from UPMC, alongside Tyler Guthrie from Owkin discuss how the MOSAIC project has the potential to be transformative in cancer research. Owkin and UPMC are partnering together to take on the spatial omics area to generate high-resolution data across entire tumor environments. From tumor cells to immune cells, fibroblasts, and blood vessels, we’re capturing how molecular features align within the tissue. Watch the full film below 👇

We’re excited to share our latest research on quantifying the hallmarks of ADC response at the upcoming European Conference on Computational Biology. Are you interested in: 🔬 How multi-omics data and advanced spatial techniques can reveal new insights into clinical success and target prioritisation for ADCs? 🧬 How MOSAIC—our comprehensive spatial and multi-omics dataset—is opening up new possibilities for biomarker discovery, drug target prioritization, and patient stratification? Join us in Liverpool on Wednesday, July 23rd, for our poster session with Christian Bromley. We look forward to connecting and exchanging ideas with the community at ISMB/ECCB!

MSIntuit® CRC has been shortlisted for the 2025 Prix Galien France award in the MedTech and Digital Solutions category. It's the first and only CE-marked AI diagnosticfor microsatellite instability (MSI) testing in colorectal cancer from digital H&E slides. Knowing a patient’s MSI status helps doctors determine who is more likely to benefit from immunotherapy, supporting more informed and personalizsed treatment decisions. Thank you to the Prix Galien jury for recognizing the importance of innovation in diagnostics. Winners will be announced in December. Learn more about MSIntuit® CRC: https://lnkd.in/ej6kU_wA

Exciting News! Our paper on MixupVI, a deep generative model for cell-type deconvolution has been accepted for presentation at ICML 2025! Join us in Vancouver on Friday, July 18th, for our poster session with Simon Grouard 🔬 MixupVI enables robust, reference-free deconvolution from RNA-seq samples containing complex cell mixtures, such as bulk and spatial transcriptomics. 📊 MixupVI accurately estimates cell type proportions—even in complex and rare populations—and achieves state-of-the-art performance in benchmarks on simulated RNA-seq mixtures. 🧑🏼💻 We’re also releasing PyDeconv, a Python library that unifies both Python- and R-based deconvolution algorithms under a common benchmarking and inference framework. We look forward to sharing our work and connecting with the community at #ICML2025! Check out the preprint and PyDeconv below: 👉 Preprint: https://lnkd.in/dQYcPgJH 👉 PyDeconv GitHub: https://lnkd.in/dwzdCaPa The team: Simon Grouard, Almudena Espín Pérez, Khalil Ouardini, Yann Rodriguez, Jean-Philippe Vert

We had a brilliant weekend at the Solve HealthCare and Life Sciences hackathon with Google France. Our team Owma tackled multimodal biomarker identification and made it to the final five! 26 teams worked through the weekend to prove that it's possible to build solutions that could change lives in just a few hours. Thank you to Google for a great event and well done team Owma: Barbara Bodinier, Nathan Bigaud, Pierre-Antoine Bannier, Vincent Cabeli and Arthur Pignet.

💡 How far has the field come with AI-driven target discovery? How far do we have yet to go? Read our new blog to find out. Over the past decade, a wave of AI-first biotech companies has emerged to disrupt the status quo - each with its own approach. This blog unpacks how AI can work as a guide for both suggesting targets and testing targets. Then we touch on how, in future, AI will become a guru that capable of far more. We explore the new techniques and data modalities that will be needed to push us towards the era of biological superintelligence. Read the blog here: https://lnkd.in/ebPTBFsd

Our co-founder and CEO Thomas Clozel is speaking at the RAISE Summit in Paris tomorrow! He’ll be on stage at 6pm to share his vision for biological superintelligence (BASI), and how we use patient data and AI to decode biology and solve medicine’s hardest problems. He’s joining an impressive line-up of global tech leaders at Le Carrousel du Louvre. If you’re going to RAISE, catch him on the Grace Hopper Stage.